Please assess the completion status of the following clinical trial:

Trial Title: FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥18 years older) with histologically proven HER2 negative adenocarcinoma or poorly differentiated carcinoma of the esophagus, GE junction tumors, and gastric cancer.~* Measurable or assessable metastatic disease.~* Performance status World Health Organization (WHO) 0-2 and life expectancy of greater than 3 months.~* No previous chemotherapy for advanced disease.~* Adequate functioning of the bone marrow, liver, and kidneys.~Exclusion Criteria:~* Breastfeeding or pregnancy.~* Active second primary cancer except in situ cancer or non-melanoma skin cancer.~* Cerebral metastases or leptomeningeal carcinomatosis.~* Severe or uncompensated concomitant medical conditions including peripheral neuropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm intervention study (Type: OTHER): Biweekly FOLFOX for two cycles alternating with FOLFIRI for two cycles (FOLFOX-FOLFIRI)

Based on this trial design, predict the completion outcome and termination type (if applicable).